FDA Brief

Warning letters Drugs

FDA warning letter to

Tattoo Numbing Cream Co.

High riskIssued Mar 25, 2024Posted Mar 26, 2024Center for Drug Evaluation and Research | CDER

Tattoo Numbing Cream Co. sold Signature Tattoo Numbing Cream and Miracle Numb Spray as unapproved drugs for tattooing.

What happened

FDA reviewed the company's website in November 2023 and found Signature Tattoo Numbing Cream and Miracle Numb Spray offered for sale and marketed for numbing before or during tattooing. FDA said the products list lidocaine 5%, above the 0.5% to 4% range allowed for nonprescription external pain-relief products, and include active-ingredient combinations and tattooing claims not permitted by the FDA order for those products.

What FDA found

  1. The products are new drugs sold without an FDA-approved application and do not meet the FDA order for nonprescription external pain-relief products.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. The products are misbranded (mislabeled under the law) because they are nonprescription drugs that do not meet section 505G and have no approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)
  3. The labels list lidocaine at 5%, which is above the 0.5% to 4% range permitted for nonprescription external pain-relief products.

    Over-the-Counter Monograph M017; section 505G of the FD&C Act, 21 U.S.C. 355h
  4. The products combine more than one “-caine” ingredient and include epinephrine, propylamine, glycerol, or purified water as active ingredients, which M017 does not permit.

    Over-the-Counter Monograph M017; section 505G of the FD&C Act, 21 U.S.C. 355h
  5. The labeling claims use for tattooing, including on broken skin, which is not an indication included in M017 or another final order.

    Over-the-Counter Monograph M017; section 505G of the FD&C Act, 21 U.S.C. 355h

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt about steps taken to address the violations, including how it will prevent recurrence, and to explain any delay if correction cannot be completed in that time. If the company believes the products are not in violation, it must include its reasoning and supporting information.

Who should pay attention

  • tattoo studios and artists who recommend numbing creams
  • retailers and marketplaces selling topical numbing products
  • brands selling nonprescription external pain-relief products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk